Scholar Rock Holding (Nasdaq:SRRK) - Hisse Senedi Fiyatı, Haberler ve Analizler

SRRK Stoklara Genel Bakış

SRRK temel anali̇z
Kar Tanesi Skoru
Değerleme	3/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	5/6
Temettüler	0/6

Ödüller

Trading at 64.4% below our estimate of its fair value

Revenue is forecast to grow 64.67% per year

Risk Analizi

Highly volatile share price over the past 3 months compared to the US market

Makes less than USD$1m in revenue ($0)

Shareholders have been diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

Scholar Rock Holding Corporation Rakipler

Keros Therapeutics

NasdaqGM:KROS

US$2.2b

Inhibrx

NasdaqGM:INBX

US$1.8b

Syndax Pharmaceuticals

NasdaqGS:SNDX

US$1.6b

CRISPR Therapeutics

NasdaqGM:CRSP

US$4.5b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Scholar Rock Holding
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$28.42
52 Haftanın En Yüksek Seviyesi	US$35.38
52 Haftanın En Düşük Seviyesi	US$6.76
Beta	0.82
11 Aylık Değişim	283.02%
3 Aylık Değişim	233.57%
1 Yıllık Değişim	133.53%
33 Yıllık Değişim	0.35%
5 Yıllık Değişim	217.54%
Halka arzdan bu yana değişim	83.35%

Son Haberler & Güncellemeler

Scholar Rock: SMA Program Strides Forward With Positive Clinical Data

Oct 07

Recent updates

Scholar Rock Holding Corporation's (NASDAQ:SRRK) Share Price Not Quite Adding Up

Apr 19

Scholar Rock: OLE Data In SMA Coupled With New CEO Make It A Buy

Oct 20

Jay Backstrom is the new CEO at Scholar Rock

Sep 20

Scholar Rock initiated at buy at Truist on platform for rare diseases and oncology

Jul 12

Brokers Are Upgrading Their Views On Scholar Rock Holding Corporation (NASDAQ:SRRK) With These New Forecasts

May 21

Broker Revenue Forecasts For Scholar Rock Holding Corporation (NASDAQ:SRRK) Are Surging Higher

Mar 08

Scholar Rock Holding Corporation (NASDAQ:SRRK) Analysts Are More Bearish Than They Used To Be

May 15

Is Scholar Rock Holding (NASDAQ:SRRK) Using Too Much Debt?

May 07

Hissedar Getirileri

	SRRK	US Biotechs	US Pazar
7D	-6.6%	-0.7%	-1.6%
1Y	133.5%	19.8%	30.8%

Getiri vs. Endüstri: SRRK exceeded the US Biotechs industry which returned 20.1% over the past year.

Getiri vs Piyasa: SRRK exceeded the US Market which returned 30.6% over the past year.

Fiyat Oynaklığı

Is SRRK's price volatile compared to industry and market?
SRRK volatility
SRRK Average Weekly Movement	101.8%
Biotechs Industry Average Movement	9.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	2.9%

İstikrarlı Hisse Senedi Fiyatı: SRRK's share price has been volatile over the past 3 months compared to the US market.

Zaman İçindeki Volatilite: SRRK's weekly volatility has increased from 52% to 102% over the past year.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2012	150	Jay Backstrom	scholarrock.com

Bir biyofarmasötik şirketi olan Scholar Rock Holding Corporation, protein büyüme faktörlerinin sinyalizasyonunun temel bir rol oynadığı ciddi hastalıkların tedavisi için ilaçların keşfi, geliştirilmesi ve dağıtımına odaklanmaktadır. Şirket, spinal musküler atrofi tedavisi için Faz 3 klinik çalışmasında olan myostatin aktivasyonunun bir inhibitörü olan Apitegromab'ı ve anti-PD-1 veya anti-PD-L1 antikor tedavileri gibi kontrol noktası inhibitörü tedavilerine dirençli kanserlerin tedavisi için Faz 1 klinik çalışmalarını tamamlayan SRK-181'i geliştirmektedir. Nöromüsküler bozukluklar, kardiyometabolik bozukluklar, kanser, fibroz ve demir kısıtlı anemi dahil olmak üzere bir dizi ciddi hastalığı tedavi etmek için yeni tedaviler sunmak üzere ürün adaylarından oluşan bir boru hattı geliştirmektedir.

Scholar Rock Holding Corporation Temel Bilgiler Özeti

Scholar Rock Holding'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
SRRK temel i̇stati̇sti̇kler
Piyasa değeri	US$2.61b
Kazançlar(TTM)	-US$203.85m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-12.8x

F/K Oranı

SRRK aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
SRRK gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$150.76m
Brüt Kâr	-US$150.76m
Diğer Giderler	US$53.08m
Kazançlar	-US$203.85m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

Nov 12, 2024

Hisse başına kazanç (EPS)	-2.22
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	37.5%

SRRK uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

SRRK Stoklara Genel Bakış

Ödüller

Risk Analizi

Scholar Rock Holding Corporation Rakipler

NasdaqGM:KROS

US$2.2b

NasdaqGM:INBX

US$1.8b

NasdaqGS:SNDX

US$1.6b

NasdaqGM:CRSP

US$4.5b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $300.00002 million.

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $300.00002 million.

Scholar Rock Holding Corporation has filed a Follow-on Equity Offering in the amount of $275 million.

Price target increased by 11% to US$29.75

Scholar Rock: SMA Program Strides Forward With Positive Clinical Data

Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 Sapphire Study in Patients with Spinal Muscular Atrophy

Recent updates

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $300.00002 million.

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $300.00002 million.

Scholar Rock Holding Corporation has filed a Follow-on Equity Offering in the amount of $275 million.

Price target increased by 11% to US$29.75

Scholar Rock: SMA Program Strides Forward With Positive Clinical Data

Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 Sapphire Study in Patients with Spinal Muscular Atrophy

Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer

Health Check: How Prudently Does Scholar Rock Holding (NASDAQ:SRRK) Use Debt?

New major risk - Financial position

Scholar Rock Holding Corporation Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal

CFO, COO & Treasurer recently sold US$85k worth of stock

Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

Scholar Rock Holding Corporation, Annual General Meeting, Jun 27, 2024

New major risk - Shareholder dilution

Health Check: How Prudently Does Scholar Rock Holding (NASDAQ:SRRK) Use Debt?

Price target increased by 8.1% to US$26.25

New minor risk - Share price stability

New major risk - Financial position

President recently sold US$183k worth of stock

Scholar Rock Announces Management Appointments

Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management

Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity

Scholar Rock: Solid Data And Good Prospects

CFO, COO & Treasurer notifies of intention to sell stock

Senior VP & Head of Research recently sold US$295k worth of stock

CFO, COO & Treasurer notifies of intention to sell stock

Price target increased by 7.1% to US$25.71

New major risk - Revenue and earnings growth

CFO, COO & Treasurer notifies of intention to sell stock

Scholar Rock, Inc. Presents New Data from Phase 1 Dragon Trial Showing Promising Anti-Tumor Activity in Anti-Pd-1 Resistant Metastaticcc Patients and Supporting Srk-181 Continued Tolerability

Price target increased by 9.8% to US$24.00

Scholar Rock Announces to Present Clinical and Biomarker Data from the Phase 1 Dragon Trial At the Sitc 38Th Annual Meeting

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $85.000006 million.

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $85.000006 million.

Scholar Rock Announces Completion of Enrollment for the Phase 3 SAPPHIRE Trial

Scholar Rock Announces New Data from the Phase 2 TOPAZ Trial Extension Period Evaluating Patient Outcomes At 36 Months of Treatment with Apitegromab

Scholar Rock Holding Corporation, Annual General Meeting, Jun 21, 2023

Scholar Rock Holding Corporation's (NASDAQ:SRRK) Share Price Not Quite Adding Up

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Scholar Rock Appoints Tracey M. Sacco as Chief Commercial Officer

Price target decreased to US$22.57

Third quarter 2022 earnings released: US$0.55 loss per share (vs US$1.02 loss in 3Q 2021)

Scholar Rock Holding Corporationa Announces Recent Phase 1 Dragon Data Show Srk-181 Continues to Be Well Tolerated with Early Indications of Efficacy

Scholar Rock Appoints Jing L. Marantz as Chief Medical Officer

Scholar Rock Holding Corporation Announces New Phase 2 TOPAZ Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMA

Scholar Rock: OLE Data In SMA Coupled With New CEO Make It A Buy

Scholar Rock Announces Chief Executive Officer Changes

Jay Backstrom is the new CEO at Scholar Rock

Second quarter 2022 earnings released: US$1.06 loss per share (vs US$0.84 loss in 2Q 2021)

Scholar Rock Holding Corporation Appoints Srinivas Akkaraju to Board of Directors

Scholar Rock initiated at buy at Truist on platform for rare diseases and oncology

Scholar Rock Holding Corporation(NasdaqGS:SRRK) dropped from Russell 2000 Growth Index

Price target decreased to US$29.00

Scholar Rock Announces New Data from the Phase 2 Topaz Trial Extension Period Evaluating Patient Outcomes After 24-Months of Treatment

Consensus revenue estimates increase by 75%

Consensus revenue estimates increase by 75%

Brokers Are Upgrading Their Views On Scholar Rock Holding Corporation (NASDAQ:SRRK) With These New Forecasts

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Scholar Rock Holding Corporation Provides Pipeline Updates